Complement and anti-α-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not in umbilical cord serum
Open Access
- 15 January 1999
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 6 (1) , 146-148
- https://doi.org/10.1038/sj.gt.3300794
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Establishment of complement-resistant retroviral vector by homologous restriction factor 20 geneGene Therapy, 1998
- Interaction of vesicular stomatitis virus-G pseudotyped retrovirus with CD34+ and CD34+CD38− hematopoietic progenitor cellsGene Therapy, 1997
- Coupled Effects of Polybrene and Calf Serum on the Efficiency of Retroviral Transduction and the Stability of Retroviral VectorsHuman Gene Therapy, 1997
- Development of Amphotropic Murine Retrovirus Vectors Resistant to Inactivation by Human SerumHuman Gene Therapy, 1996
- A Novel Human Amphotropic Packaging Cell Line: High Titer, Complement Resistance, and Improved SafetyVirology, 1996
- Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune ResponseHuman Gene Therapy, 1996
- A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.The Journal of Experimental Medicine, 1995
- Scientific approach to ski safetyNature, 1995
- Protection of Retroviral Vector Particles in Human Blood Through Complement InhibitionHuman Gene Therapy, 1995
- Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir. National Institutes of HealthHuman Gene Therapy, 1993